"Exceptions that prove the rule"-Why have clinical trials failed to show efficacy of risk factor interventions suggested by observational studies of the dementia-Alzheimer's disease syndrome?
作者信息
Breitner John C S, Dodge Hiroko H, Khachaturian Zaven S, Khachaturian Ara S
机构信息
Douglas Hospital Research Center and McGill University, Montreal, Quebec, Canada.
Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA.
出版信息
Alzheimers Dement. 2022 Mar;18(3):389-392. doi: 10.1002/alz.12633. Epub 2022 Mar 4.
Abstract
摘要
相似文献
1
"Exceptions that prove the rule"-Why have clinical trials failed to show efficacy of risk factor interventions suggested by observational studies of the dementia-Alzheimer's disease syndrome?
Alzheimers Dement. 2022 Mar;18(3):389-392. doi: 10.1002/alz.12633. Epub 2022 Mar 4.
2
Utilization of Observational Data as a Proxy Cohort for Comparison Purposes with Open-Label Study Results: An Example from Alzheimer's Disease.
J Prev Alzheimers Dis. 2019;6(2):90-99. doi: 10.14283/jpad.2019.4.
3
Nimodipine for primary degenerative, mixed and vascular dementia.
Cochrane Database Syst Rev. 2001(1):CD000147. doi: 10.1002/14651858.CD000147.
4
Alzheimer's dementia: current data review.
Coll Antropol. 2011 Dec;35(4):1333-7.
5
Nimodipine for primary degenerative, mixed and vascular dementia.
Cochrane Database Syst Rev. 2002(3):CD000147. doi: 10.1002/14651858.CD000147.
6
WITHDRAWN: Tacrine for Alzheimer's disease.
Cochrane Database Syst Rev. 2007 Jul 18(3):CD000202. doi: 10.1002/14651858.CD000202.
7
Protection against Brain Atrophy by Anti-dementia Medication in Mild Cognitive Impairment and Alzheimer's Disease: Meta-Analysis of Longitudinal Randomized Placebo-Controlled Trials.
Int J Neuropsychopharmacol. 2015 Jun 19;18(12):pyv070. doi: 10.1093/ijnp/pyv070.
8
Can statin therapy really reduce the risk of Alzheimer's disease and slow its progression?
Curr Opin Lipidol. 2005 Dec;16(6):619-23. doi: 10.1097/01.hjh.0000191246.68443.ff.
9
Rivastigmine for Alzheimer's disease.
Cochrane Database Syst Rev. 2015 Apr 10(4):CD001191. doi: 10.1002/14651858.CD001191.pub3.
10
Interventions for heart disease and their effects on Alzheimer's disease.
Neurol Res. 2006 Sep;28(6):630-6. doi: 10.1179/016164106X130515.
引用本文的文献
1
Perspective: Emerging challenges for a future ADNI.
Alzheimers Dement. 2025 Feb;21(2):e14534. doi: 10.1002/alz.14534.
2
The Effects of Social Interaction Intervention on Cognitive Functions Among Older Adults Without Dementia: A Systematic Review and Meta-Analysis.
Innov Aging. 2024 Oct 3;8(10):igae084. doi: 10.1093/geroni/igae084. eCollection 2024.
3
Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History.
J Clin Med. 2024 Jan 17;13(2):536. doi: 10.3390/jcm13020536.
4
Pathogenesis of Alzheimer's disease: Involvement of the choroid plexus.
Alzheimers Dement. 2023 Aug;19(8):3537-3554. doi: 10.1002/alz.12970. Epub 2023 Feb 24.
5
Biomarkers of Alzheimer syndrome and related dementias: A&D author's guide.
Alzheimers Dement. 2022 Sep;18(9):1595-1601. doi: 10.1002/alz.12772. Epub 2022 Aug 25.
本文引用的文献
1
Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in-depth exploration of seven established risk factors.
Alzheimers Dement (N Y). 2021 Dec 8;7(1):e12202. doi: 10.1002/trc2.12202. eCollection 2021.
2
The epidemiology is promising, but the trial evidence is weak. Why pharmacological dementia risk reduction trials haven't lived up to expectations, and where do we go from here?
Alzheimers Dement. 2022 Mar;18(3):507-512. doi: 10.1002/alz.12393. Epub 2021 Nov 2.
3
Hypothesis: cerebrospinal fluid protein markers suggest a pathway toward symptomatic resilience to AD pathology.
Alzheimers Dement. 2019 Sep;15(9):1160-1171. doi: 10.1016/j.jalz.2019.05.007. Epub 2019 Aug 9.
4
Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development.
Alzheimers Dement (N Y). 2016 Sep 20;3(1):83-91. doi: 10.1016/j.trci.2016.09.002. eCollection 2017 Jan.
5
Calcium Hypothesis of Alzheimer's disease and brain aging: A framework for integrating new evidence into a comprehensive theory of pathogenesis.
Alzheimers Dement. 2017 Feb;13(2):178-182.e17. doi: 10.1016/j.jalz.2016.12.006. Epub 2017 Jan 3.
6
Risk of incident clinical diagnosis of Alzheimer's disease-type dementia attributable to pathology-confirmed vascular disease.
Alzheimers Dement. 2017 Jun;13(6):613-623. doi: 10.1016/j.jalz.2016.11.003. Epub 2016 Dec 23.
7
Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury.
Sci Transl Med. 2016 Dec 14;8(369):369ra178. doi: 10.1126/scitranslmed.aag1767.
8
Big data to smart data in Alzheimer's disease: Real-world examples of advanced modeling and simulation.
Alzheimers Dement. 2016 Sep;12(9):1022-1030. doi: 10.1016/j.jalz.2016.05.005. Epub 2016 Jun 18.
9
Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge.
Alzheimers Dement. 2016 Sep;12(9):1014-1021. doi: 10.1016/j.jalz.2016.04.008. Epub 2016 May 26.
10
The Special Topics Section of Alzheimer's & Dementia.
Alzheimers Dement. 2015 Nov;11(11):1261-4. doi: 10.1016/j.jalz.2015.10.002.
Zotero 插件